CROWE v. MAXA

CourtDistrict Court, W.D. Pennsylvania
DecidedAugust 29, 2019
Docket1:16-cv-00175
StatusUnknown

This text of CROWE v. MAXA (CROWE v. MAXA) is published on Counsel Stack Legal Research, covering District Court, W.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CROWE v. MAXA, (W.D. Pa. 2019).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA

DANIEL CROWE, ) ) Plaintiff ) Case No. 1:16-175 Erie ) Vv. ) ) ROBERT MAXA, ) RICHARD A. LANZILLO ) UNITED STATES MAGISTRATE JUDGE Defendant ) ) OPINION ON DEFENDANT’S ) MOTION TO DISMISS ) [ECF NO. 44] MEMORANDUM OPINION Presently pending before the Court is Defendant’s Motion to Dismiss [ECF No. 44] Plaintiff's Amended Complaint pursuant to Federal Rule of Civil Procedure 12(b)(6). For the reasons discussed below, the Court will grant Defendant’s motion.!

I. Procedural History Plaintiff Daniel Crowe, an inmate at the State Correctional Institution at Albion, commenced this civil rights action pursuant to 42 U.S.C. § 1983 on September 7, 2016 by filing a Complaint alleging that Defendant Robert Maxa (“Dr. Maxa’’), the prison physician, violated his Eighth Amendment rights by denying him necessary medical care. Dr. Maza moved to dismiss Plaintiff's Complaint pursuant to Rule 12(b)(6), arguing that it failed to allege facts sufficient to support a plausible claim that Dr. Maxa acted with deliberate indifference to Plaintiff's serious medical needs. ECF. No. 29. On November 9, 2018, this Court granted

' The parties have consented to the jurisdiction of the undersigned United States Magistrate Judge pursuant to 28 U.S.C. § 636. See ECF Nos. 9, 33.

Defendant’s Motion to Dismiss, but also granted Plaintiff leave to file an amended complaint in an effort to cure the deficiencies of his claim. ECF No. 41. Plaintiff filed an Amended Complaint on November 30, 2018. ECF No. 43. Dr. Maxa filed the pending Motion to Dismiss the Amended Complaint on December 20, 2018. ECF No. 44. Plaintiff responded to the motion on February 1, 2019. ECF No. 47. Dr. Maxa filed a reply brief on February 4, 2019. ECF No. 48. Plaintiff filed a sur-reply on February 28, 2019. ECF No. 49. The motion has been fully briefed and is ripe for disposition.

II. Factual Allegations In his Amended Complaint, Plaintiff alleges that he went to a sick call appointment with Dr. Maxa for back pain on December 4, 2015. ECF No. 43, 9 6. Dr. Maxa reviewed a recent MRI and informed Plaintiff that he had degenerative disc disease in his spine. /d. at J 7. Plaintiff then specifically requested Ultram, a prescription medication for his pain. Jd. at Jf 8, 10). Dr. Maxa refused to prescribe this medication, telling Plaintiff that Ultram was not on the Department of Correction’s list of approved medications for financial reasons.” Jd. at § 10. Plaintiff further alleges that he told Dr. Maxa that this was deliberate indifference to his medical care and that Dr. Maxa ended the visit by “denying any and all treatment.” /d. at JJ 11-13.

2 Ultram is the brand name of a drug called Tramadol. See www.mayoclinic.org/drugssupplements/tramadol-oral- route/description/drg-20068050 (last visited August 28, 2018). According to the Mayo Clinic, Tramadol is an opioid analgesic used to relieve moderate to moderately severe pain. Jd. When “used for a long time, it may become habit- forming, causing mental or physical dependence.” /d. The Court may take judicial notice of these background facts pursuant to Federal Rule of Evidence 201(b)(2) because they are “not subject to reasonable dispute [and are] capable of accurate and ready determination by resort to a source whose accuracy cannot be reasonably questioned.” See, e.g., Rankins v. Washington, 2017 WL 4364060, at *3 (W.D. Mich. Sep. 29, 2017) (taking judicial notice of facts presented on the Mayo Clinic’s website); Giddings v. Cradduck, 2017 WL 2791345, at *6 n. 4 (W.D. Ark. June 6, 2017) (same); Green v. CDCR, 2016 WL 6124148, at *1 n. 1 (E.D. Cal. Oct. 19, 2016) (same); Arce v. Chicago Transit Authority, 193 F.Supp.3d 875, 881 (N.D. Ill. 2016) (same).

In the grievance from this encounter, which Plaintiff attached to his Amended Complaint, Plaintiff further alleged that Dr. Maxa “prescribed ‘NSAID’ medications even though I told him they were not effective from my experience... .”? ECF No 43-1. Plaintiffs grievance states that this prescription was provided during Plaintiff's first meeting with Dr. Maxa, which meeting Plaintiff identifies as having occurred on December 4, 2015. Jd. Il. Standards of Review 1. Pro se Litigants Pro se pleadings, “however inartfully pleaded,” must be held to “less stringent standards than formal pleadings drafted by lawyers.” Haines y. Kerner, 404 U.S. 519, 520-521 (1972). If the court can reasonably read pleadings to state a valid claim on which the litigant could prevail, it should do so despite failure to cite proper legal authority, confusion of legal theories, poor syntax and sentence construction, or litigant’s unfamiliarity with pleading requirements. Boag v. MacDougall, 454 U.S. 364 (1982); United States ex rel. Montgomery v. Bierley, 141 F.2d 552, 555 (3d Cir. 1969) (petition prepared by a prisoner may be inartfully drawn and should be read “with a measure of tolerance”); Smith v. U.S. District Court, 956 F.2d 295 (D.C. Cir. 1992); Freeman v. Dep't of Corrections, 949 F.2d 360 (10th Cir. 1991). Under our liberal pleading rules, during the initial stages of litigation, a district court should construe all! allegations in a complaint in favor of the complainant. Gibbs v. Roman, 116 F.3d 83 (3d Cir. 1997). See, e.g.,

3 The acronym “NSAID” refers to “nonsteroidal anti-inflammatory drugs,” such as naproxen sodium, ibuprofen, and others. See https://www.mayoclinic.org/chronic-pain-medication-decisions/art- 20360371?mc_id=us&utm_source=newsnetwork&utm_medium=l&utm_content=content&utm_campaign=mayocli nic&geo=national&placementsite=enterprise&cauid=100721& ga=2.160092664.473 568632. 1567020980- 51837601.1566583588 (last visited August 28, 2019). NSAIDs are most effective for mild to moderate pain that's accompanied by swelling and inflammation. /d. These drugs are commonly used for arthritis and pain resulting from muscle sprains, strains, back and neck injuries, or menstrual cramps. /d.

Nami v. Fauver, 82 F.3d 63, 65 (3d Cir. 1996) (discussing Fed. R. Civ. P. 12(b)(6) standard); Markowitz v. Northeast Land Co., 906 F.2d 100, 103 (3d Cir. 1990) (same). 2. Motion to dismiss A motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6) tests the legal sufficiency of the complaint. Kost v. Kozakiewicz, 1 F.3d 176, 183 (3d Cir. 1993). In deciding a motion to dismiss, the court is not opining on whether the plaintiff will be likely to prevail on the merits; rather, the plaintiff must only present factual allegations sufficient “to raise a right to relief above the speculative level.” Bell Atlantic Corp. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
Haines v. Kerner
404 U.S. 519 (Supreme Court, 1972)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Boag v. MacDougall
454 U.S. 364 (Supreme Court, 1982)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Santiago v. Warminster Township
629 F.3d 121 (Third Circuit, 2010)
F. Winslow v. Prison Health Services
406 F. App'x 671 (Third Circuit, 2011)
Russell E. Freeman v. Department of Corrections
949 F.2d 360 (Tenth Circuit, 1991)
Burtch v. Milberg Factors, Inc.
662 F.3d 212 (Third Circuit, 2011)
Nami v. Fauver
82 F.3d 63 (Third Circuit, 1996)
Morse v. Lower Merion School District
132 F.3d 902 (Third Circuit, 1997)
U.S. Express Lines, Ltd. v. Higgins
281 F.3d 383 (Third Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
CROWE v. MAXA, Counsel Stack Legal Research, https://law.counselstack.com/opinion/crowe-v-maxa-pawd-2019.